Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-002 and IMM0306S in Active Systemic Lupus Erythematosus
NCT06535412Phase 2Recruiting
- Sponsor
- ImmuneCare (Suzhou) Biopharmaceuticals Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing IMC-002 + SOC, Placebo + SOC and IMM0306S + SOC (3 arms). Primary endpoints: SLE Responder Index at 24 weeks, Adverse Events and Serious Adverse Events at 52 weeks and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
IMC-002IMM0306S
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06535412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06535412.